“This year's review highlighted the genesis of a new upswing in dealmaking fortunes in the industry. DealForma data coupled with the sentiment emerging from a bumper JPM Health Care Conference in San Francisco offer reason to believe that the life sciences is primed for a very good 2024.”
/ eBooks
Biopharma dealmaking 2024: trends, analysis, forecasts
It's been a difficult year for biopharma dealmaking but there might be light at the end of the tunnel.
Share:
Download this free eBook
A bumper year for biopharma?
— Gilles Toulemonde, CEO at Inpart